BioCryst Pharmaceuticals Inc. (BCRX) Hits New 52-week Low During January 19 Session

Equities Staff |

BioCryst Pharmaceuticals Inc. (BCRX) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $7.61, BioCryst Pharmaceuticals Inc. dropped to $6.86 for a new 52-week low. By the closing bell, the company's stock was at $6.88 a share for a loss of 7.77%.

Falling to a new 52-week low is never fun for company's shareholder, but, depending on who you ask, it can be either a buy or a sell signal. Someone bearish on the stock might see it reaching its lowest price in a year as a sign of growing downward momentum and make sure they sell their shares. Bulls, though, are more likely to see a new 52-week low as the stock hitting its low point and anticipate a bounce in the share price.

However one plays it, it's often a critical moment for any stock and should be noted by investors.

BioCryst Pharmaceuticals Inc. saw 587,489 shares of its stock trade hands, that's out of 73.34 million shares outstand. The stock has an average daily volume of 849,729 shares. After hitting a new 52-week low, BioCryst Pharmaceuticals Inc. enters the new trading day with a market cap of 504.56 million, a 50-day SMA of $9.82 and a 200-day SMA of $11.41

For a complete fundamental analysis analysis of BioCryst Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for BCRX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

Biocryst Pharmaceuticals Inc is a biotechnology company. The Company designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases.

BioCryst Pharmaceuticals Inc. has 50 employees, is led by CEO Jon P. Stonehouse, and makes its home in Durham, NC.

BioCryst Pharmaceuticals Inc. is also a component of the Russell 2000 Index, which is generally viewed as the most reliable indicator of the health of the broader small-cap market. Using a rules-based methodology, it creates a simple, unbiased view of how America's stable of smaller publicly traded companies are performing in the stock markets.

The index consists of the 2,000 smallest companies of the 3,000 largest publicly-traded companies in the country as judged by market cap. It's constructed by Russell Investments, which also builds and maintains the Russell 3000 (an index consisting of all 3,000 biggest companies by market cap) and the large-cap Russell 1000 (which has the 1,000 largest companies from the Russell 3000).

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Relevium Technologies Inc.

Relevium Technologies Inc is engaged in the acquisition of products, technologies and businesses relating to musculoskeletal function, specifically Pain Relief, Injury Recovery and Active Performance.

Private Markets

Knightscope

Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…